MX343167B - Metodos y composiciones para identificar y tratar lupus. - Google Patents

Metodos y composiciones para identificar y tratar lupus.

Info

Publication number
MX343167B
MX343167B MX2009012531A MX2009012531A MX343167B MX 343167 B MX343167 B MX 343167B MX 2009012531 A MX2009012531 A MX 2009012531A MX 2009012531 A MX2009012531 A MX 2009012531A MX 343167 B MX343167 B MX 343167B
Authority
MX
Mexico
Prior art keywords
methods
identifying
compositions
treating lupus
lupus
Prior art date
Application number
MX2009012531A
Other languages
English (en)
Other versions
MX2009012531A (es
Inventor
Timothy W Behrens
Geoffrey Hom
Ward A Ortmann
Robert Royal Graham
Original Assignee
Genentech Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc * filed Critical Genentech Inc *
Publication of MX2009012531A publication Critical patent/MX2009012531A/es
Publication of MX343167B publication Critical patent/MX343167B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2533/00—Reactions characterised by the enzymatic reaction principle used
    • C12Q2533/10—Reactions characterised by the enzymatic reaction principle used the purpose being to increase the length of an oligonucleotide strand
    • C12Q2533/101—Primer extension
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para diagnosticar lupus o valorar el riesgo de desarrollar lupus en un sujeto, el método comprendiendo: a) detectar en una muestra biológica del sujeto, la presencia de una firma genética indicativa de lupus o riesgo de desarrollar lupus, en donde dicha firma genética comprende la ausencia de un alelo menor de polimorfismo de nucleótido sencillo (SNP) rs4963128 y la presencia de un alelo menor de SNP rs2269368; y b) terminar que el sujeto tiene lupus o está en riesgo de desarrollar lupus cuando la firma genética se encuentra presente.
MX2009012531A 2007-05-21 2008-05-21 Metodos y composiciones para identificar y tratar lupus. MX343167B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93915607P 2007-05-21 2007-05-21
US1328307P 2007-12-12 2007-12-12
PCT/US2008/064430 WO2008144761A2 (en) 2007-05-21 2008-05-21 Methods and compositions for identifying and treating lupus

Publications (2)

Publication Number Publication Date
MX2009012531A MX2009012531A (es) 2009-12-03
MX343167B true MX343167B (es) 2016-10-26

Family

ID=40122294

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010728A MX353428B (es) 2007-05-21 2008-05-21 Métodos y composiciones para identificar y tratar lupus.
MX2009012531A MX343167B (es) 2007-05-21 2008-05-21 Metodos y composiciones para identificar y tratar lupus.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016010728A MX353428B (es) 2007-05-21 2008-05-21 Métodos y composiciones para identificar y tratar lupus.

Country Status (14)

Country Link
US (1) US20110046094A1 (es)
EP (3) EP2158335A2 (es)
JP (4) JP5728226B2 (es)
KR (4) KR101729431B1 (es)
CN (3) CN108753946A (es)
AU (1) AU2008254582A1 (es)
BR (1) BRPI0811930B8 (es)
CA (1) CA2690608C (es)
ES (1) ES2661249T3 (es)
HK (3) HK1209459A1 (es)
IL (1) IL201949A0 (es)
MX (2) MX353428B (es)
RU (1) RU2009147281A (es)
WO (1) WO2008144761A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158335A2 (en) * 2007-05-21 2010-03-03 Genetech, Inc. Methods and compositions for identifying and treating lupus
AU2009296393A1 (en) * 2008-09-26 2010-04-01 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
US20100105061A1 (en) * 2008-10-29 2010-04-29 University Of Southern California Autoimmune genes identified in systemic lupus erythematosus (sle)
CA2749869A1 (en) * 2009-03-03 2010-09-10 Merck Serono S.A. Bank1 related snps and sle and/or ms susceptibility
WO2011044205A1 (en) * 2009-10-07 2011-04-14 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
WO2011109338A1 (en) * 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Methods and compositions for treating degos' disease
EP2673372A4 (en) * 2011-02-10 2014-11-19 Genqual Corp METHODS OF PROGNOSIS AND DELIVERY OF TREATMENT FOR INFLAMMATORY DISORDERS
US20130317006A1 (en) 2012-05-24 2013-11-28 Amy Yasko Use of polymorphisms for identifying individuals at risk of developing autism
WO2015081052A1 (en) 2013-11-27 2015-06-04 Yasko Amy Use of polymorphisms for identifying individuals at risk of developing autism
WO2016207647A1 (en) * 2015-06-24 2016-12-29 Oxford Biodynamics Limited Epigenetic chromosome interactions
CN110459312B (zh) * 2018-05-07 2024-01-12 深圳华大生命科学研究院 类风湿性关节炎易感位点及其应用
WO2021127589A1 (en) * 2019-12-18 2021-06-24 The Children's Hospital Of Philadelphia Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same
KR20240021336A (ko) 2022-08-09 2024-02-19 심재홍 수액 채취장치의 냉각기 구조

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) * 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2255774C (en) * 1996-05-29 2008-03-18 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
CA2410950A1 (en) 2000-05-30 2001-12-06 Hans-Michael Wenz Methods for detecting target nucleic acids using coupled ligation and amplification
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
IL155450A0 (en) * 2000-10-20 2003-11-23 Expression Diagnostics Inc Leukocyte expression profiling
US7205106B1 (en) * 2001-07-20 2007-04-17 Roche Molecular Systems, Inc. Association of polymorphisms in IL4-related genes with autoimmune disease
JP2003061677A (ja) * 2001-08-28 2003-03-04 Olympus Optical Co Ltd 全身性エリテマトーデスの感受性遺伝子およびその使用
US20030119004A1 (en) 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
IL163600A0 (en) * 2002-03-01 2005-12-18 Ravgen Inc Methods for detection of genetic disorders
WO2004083403A2 (en) * 2003-03-18 2004-09-30 Applera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2005086872A2 (en) * 2004-03-10 2005-09-22 Celera, An Applera Corporation Business Ptpn22 polymorphisms in diagnosis and therapy
WO2006097463A2 (en) 2005-03-15 2006-09-21 Ares Trading S.A. Compositions and methods for treating and diagnosing inflammatory disorders
CA2614455A1 (en) 2005-08-05 2007-02-15 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
EP2158335A2 (en) * 2007-05-21 2010-03-03 Genetech, Inc. Methods and compositions for identifying and treating lupus
AU2009296393A1 (en) * 2008-09-26 2010-04-01 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus

Also Published As

Publication number Publication date
HK1189246A1 (en) 2014-05-30
BRPI0811930A2 (pt) 2014-11-25
RU2009147281A (ru) 2011-06-27
KR20190015629A (ko) 2019-02-13
ES2661249T3 (es) 2018-03-28
WO2008144761A2 (en) 2008-11-27
CA2690608C (en) 2020-07-21
CN108753946A (zh) 2018-11-06
JP5728226B2 (ja) 2015-06-03
CN104593488B (zh) 2018-06-12
US20110046094A1 (en) 2011-02-24
WO2008144761A3 (en) 2009-07-02
JP2018126146A (ja) 2018-08-16
KR20100021612A (ko) 2010-02-25
MX353428B (es) 2018-01-12
HK1255086A1 (zh) 2019-08-02
MX2009012531A (es) 2009-12-03
KR101947093B1 (ko) 2019-02-12
CA2690608A1 (en) 2008-11-27
AU2008254582A1 (en) 2008-11-27
BRPI0811930B1 (pt) 2019-11-05
HK1209459A1 (en) 2016-04-01
KR20150133861A (ko) 2015-11-30
EP2158335A2 (en) 2010-03-03
EP2612924A3 (en) 2013-10-23
EP2612924B1 (en) 2017-12-20
EP2612924A2 (en) 2013-07-10
KR101651678B1 (ko) 2016-08-26
CN103298950A (zh) 2013-09-11
JP2015164426A (ja) 2015-09-17
KR20170042831A (ko) 2017-04-19
JP6080059B2 (ja) 2017-02-15
CN104593488A (zh) 2015-05-06
BRPI0811930B8 (pt) 2021-05-25
JP2017035088A (ja) 2017-02-16
EP3318643A3 (en) 2018-06-20
IL201949A0 (en) 2010-06-16
JP2010528590A (ja) 2010-08-26
CN103298950B (zh) 2015-01-21
EP3318643A2 (en) 2018-05-09
KR101729431B1 (ko) 2017-04-21

Similar Documents

Publication Publication Date Title
MX343167B (es) Metodos y composiciones para identificar y tratar lupus.
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
WO2010001419A3 (en) Copy number variations predictive of risk of schizophrenia
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
MY150648A (en) Hla alleles associated with adverse drug reactions and methods for detecting such
WO2010036969A3 (en) Genetic markers for assessing risk of developing schizophrenia
MY150234A (en) Predictive markers for ovarian cancer
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
PT2121963E (pt) Métodos para identificar uma estirpe isolada a partir de uma amostra clínica ao nível da espécie e/ou subespécie
EP2582847A4 (en) METHOD AND MATERIALS FOR EVALUATING THE LOSS OF HETEROZYGOTY
EP2518158A4 (en) PANCREATIC CANCER MARKERS, METHODS, KITS AND DETECTION BIOPUCES THEREFOR
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
WO2009120561A3 (en) Methods and gene expression signature for assessing growth factor signaling pathway regulation status
DK2002016T3 (da) Fremgangsmåde til bestemmelse af kopital
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2009086215A3 (en) Pathway analysis of cell culture phenotypes and uses thereof
WO2006092610A3 (en) Markers for melanoma
EA201291228A1 (ru) Биомаркер для детекции высокогорной адаптации и высокогорного отека легких
MX2007013727A (es) Caracterizacion de cancer de prostata.
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
MX2009004382A (es) Variaciones geneticas asociadas con tumores.
MX2012000041A (es) Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.
WO2013077814A3 (en) Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
WO2008018789A3 (en) Methods and means for diagnosing and treatment of osteoarthritis

Legal Events

Date Code Title Description
FG Grant or registration